Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Breast Cancer Clinical Trial

Official title:

A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00541086
• Other study ID #: CDR0000570041
• Secondary ID: GIM-3-FATAEUDRAC
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 2007
• Est. completion date: July 2020

Study information

• Verified date: February 2020
• Source: Gruppo Italiano Mammella (GIM)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking use of estrogen by the tumor cells. Anastrozole, letrozole, and exemestane may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether giving tamoxifen followed by anastrozole, letrozole, or exemestane is more effective than giving anastrozole, letrozole, or exemestane alone in treating breast cancer.

PURPOSE: This randomized phase III trial is studying giving tamoxifen followed by either anastrozole, letrozole, or exemestane to see how well it works compared to anastrozole, letrozole, or exemestane alone in treating postmenopausal women with hormone-responsive invasive breast cancer that has been completely removed by surgery.

Description:

OBJECTIVES:

• To compare sequential tamoxifen for 2 years followed by anastrozole, letrozole, or exemestane for 3 years vs anastrozole, letrozole, or exemestane for 5 years in terms of disease-free survival in postmenopausal women with nonrecurrent, nonmetastatic invasive endocrine-responsive breast cancer.

• To compare disease-free survival in patients treated with anastrozole vs letrozole vs exemestane.

OUTLINE: This is a multicenter study. Patients are stratified according to hormone receptor status (estrogen receptor [ER]-positive and progesterone [PgR] receptor-positive disease vs ER-positive and PgR-negative disease vs ER-negative and PgR-positive disease vs ER- or PgR-positive disease or ER or PgR status unknown), HER-2/neu status (positive [3+ by IHC or positive by fluorescence in situ hybridization ( FISH)] vs negative vs unknown), prior chemotherapy (none vs adjuvant vs neoadjuvant vs both adjuvant and neoadjuvant), and nodal status (pN0 vs pN1 vs pN2 vs pN3). Patients are randomized to 1 of 6 treatment arms.

• Arm I: Patients receive oral anastrozole once daily for 5 years.

• Arm II: Patients receive oral exemestane once daily for 5 years.

• Arm III: Patients receive oral letrozole once daily for 5 years.

• Arm IV: Patients receive oral tamoxifen citrate once daily for 2 years followed by oral anastrazole once daily for 3 years.

• Arm V: Patients receive oral tamoxifen citrate once daily for 2 years followed by oral exemestane once daily for 3 years.

• Arm VI: Patients receive oral tamoxifen citrate once daily for 2 years followed by oral letrozole once daily for 3 years.

Treatment in all arms continues in the absence of disease recurrence or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3697
• Est. completion date: July 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed invasive breast cancer completely removed by surgery

• Any T, any N

• No recurrent or metastatic disease

• Estrogen or progesterone receptor-positive disease in primary tumor, as defined by 1 of the following:

• At least 10% of tumor cells positive by immunohistochemistry

• At least 10 fmol/mg cytosol protein by ligand binding assay

• Patients with HER-2/neu positive tumors are eligible provided they receive trastuzumab (Herceptin®) according to the registered schedule

PATIENT CHARACTERISTICS:

• Female

• Postmenopausal, defined by = 1 of the following:

• Age = 60 years

• Age 45-59 and satisfying 1 or more of the following criteria:

• Amenorrhea for = 12 months AND intact uterus

• Amenorrhea (secondary to hysterectomy, hormone replacement therapy (HRT), or chemotherapy) for < 12 months AND follicle-stimulating hormone within the postmenopausal range

• Underwent prior bilateral oophorectomy at any age >18 years

• No concurrent illness that contraindicates adjuvant endocrine treatment

• No other invasive breast cancer or invasive malignancy within the past 10 years, except adequately cone-biopsied squamous cell or basal cell skin cancer or carcinoma in situ of the cervix

• No concurrent disease that would place the patient at unusual risk

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Adjuvant or neoadjuvant chemotherapy must be completed prior to study entry

• At least 1 month since prior and no concurrent HRT

• More than 30 days since prior systemic investigational drugs

• No prior tamoxifen as part of any breast cancer prevention study

• Prior or concurrent locoregional radiotherapy allowed

• No other concurrent experimental drugs

• No concurrent bisphosphonates, unless indicated as treatment for osteoporosis

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• anastrozole
1 mg per day, orally
• exemestane
25 mg per day, orally
• letrozole
2.5 mg per day, orally
• tamoxifen citrate
20 mg per day, orally

Locations

Country	Name	City	State
Italy	Federico II University Medical School	Naples
Italy	Istituto Nazionale per lo Studio e la Cura dei Tumori	Naples
Italy	Seconda Universita di Napoli	Naples
Italy	Arcispedale S. Maria Nuova	Reggio Emilia
Italy	Istituti Fisioterapici Ospitalieri - Roma	Rome

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Italiano Mammella (GIM)

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival		5 years
Secondary	Overall Survival		5 years
Secondary	Distant metastasis-free survival		5 years
Secondary	Cumulative incidence of contralateral breast cancer as first event		5 years
Secondary	Breast cancer-free survival		5 years
Secondary	Cumulative incidence and type of second non-breast invasive cancer		5 years
Secondary	Effects on lipid profile		5 years
Secondary	Toxicity as assessed by NCI CTCAE v3.0		5 years